Literature DB >> 24307431

Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.

Francesca Ingegnoli1, Athanasia Tourlaki, Roberta Gualtierotti.   

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24307431     DOI： 10.1007/s40261-013-0159-9

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   3.580


  17 in total

1.  Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy.

Authors:  C D Cohen; S Horster; C A Sander; J R Bogner
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

2.  Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab.

Authors:  Francesco Ursini; Saverio Naty; Valerio Mazzei; Francesco Spagnolo; Rosa Daniela Grembiale
Journal:  Int Immunopharmacol       Date:  2010-04-28       Impact factor: 4.932

3.  [Kaposi sarcoma associated with infliximab treatment].

Authors:  M L Martínez-Martínez; L J Pérez-García; E Escario-Travesedo; P A Ribera-Vaquerizo
Journal:  Actas Dermosifiliogr       Date:  2010-06

4.  HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Authors:  Paolo Nicoli; Ubaldo Familiari; Marco Bosa; Tiziano Allice; Francesca Mete; Alessandro Morotti; Daniela Cilloni; Giuseppe Saglio; Angelo Guerrasio
Journal:  Int J Hematol       Date:  2009-09-12       Impact factor: 2.490

5.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element.

Authors:  Jiabin An; Alan K Lichtenstein; Gregory Brent; Matthew B Rettig
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab.

Authors:  Yasushi Terasaki; Hirokazu Okumura; Katsuhiko Saito; Yasuharu Sato; Tadashi Yoshino; Ryo Ichinohasama; Youichi Ishida
Journal:  Intern Med       Date:  2008-12-15       Impact factor: 1.271

8.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

Authors:  Mark C Genovese; James D McKay; Evgeny L Nasonov; Eduardo F Mysler; Nilzio A da Silva; Emma Alecock; Thasia Woodworth; Juan J Gomez-Reino
Journal:  Arthritis Rheum       Date:  2008-10

9.  Pathology of rituximab-induced Kaposi sarcoma flare.

Authors:  Liron Pantanowitz; Klaus Früh; Sharon Marconi; Ashlee V Moses; Bruce J Dezube
Journal:  BMC Clin Pathol       Date:  2008-07-23

10.  Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).

Authors:  Maxime Dougados; Karsten Kissel; Tom Sheeran; Paul P Tak; Philip G Conaghan; Emilio Martín Mola; Georg Schett; Howard Amital; Federico Navarro-Sarabia; Antony Hou; Corrado Bernasconi; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103
View more
  2 in total

1.  Authors' reply to Verdelli et al.: there is no knowledge without experience.

Authors:  Francesca Ingegnoli; Athanasia Tourlaki; Roberta Gualtierotti
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

2.  Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma.

Authors:  Alice Verdelli; Diletta Bonciani; Veronica Bonciolini; Marzia Caproni
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.